Developer docs
API playgroundTry for free, no card

Search company profiles

Winterlight Labs

Full company profile

uuid0002thy

Namestring
Winterlight Labs
Legal namestring
Winterlight Labs, Inc.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Winterlight Labs is a Toronto-based digital health company, founded in 2015 and spun out of the University of Toronto, that builds proprietary speech-analysis technology to detect and monitor cognitive impairment from short (1-5 minute) recorded speech samples. The platform combines natural language processing, computational linguistics, cognitive neuroscience and machine learning to extract 550+ acoustic and linguistic features (e.g., informativeness, coherence, repetition, preposition/pronoun use, speaking rate, pauses, filled pauses, spectral composition) and produce speech-based digital biomarkers for conditions including Alzheimer's disease, frontotemporal dementia, mild cognitive impairment, Parkinson's, ALS, depression, schizophrenia and hepatic encephalopathy. Multi-language linguistic analysis is supported across English, French, Spanish and German via the Universal Dependencies framework. The product surface comprises the Winterlight Assessment (a tablet- or device-based cognitive assessment for in-clinic or remote use), a Speech Analysis API (waitlist-based) for partners with existing speech data, and a Clinical Assessment Ratings Quality Assurance service that automates 100% review of clinical assessment administration and scoring (ADAS-Cog, CDR, MMSE, MoCA, PANSS, HAM-D).

Winterlight's go-to-market is predominantly enterprise sales to pharmaceutical and life sciences customers (the company states it is "trusted by five of the top ten Life Sciences companies"), with named deployments across a dozen clinical trials at Genentech, Janssen Pharmaceuticals, Alector, Vivoryon Therapeutics, Cortexyme and Pear Therapeutics. Revenue is generated through clinical research collaborations (professional services for site onboarding, data collection, analysis and interpretation), technology licensing (e.g., Pear Therapeutics for prescription digital therapeutics), and prospective API subscriptions. Senior care pilots (e.g., Revera) and academic collaborations (University of Toronto, Amsterdam UMC, McMaster, CAMH, Sunnybrook, University of Michigan) serve as validation and data-collection channels rather than primary monetization. In November 2019 the company closed a CAD 5.6M oversubscribed Series A led by Hikma Ventures; in January 2023 Cambridge Cognition Holdings Plc acquired Winterlight for approximately $8.6M, integrating it as a wholly owned subsidiary with combined capabilities in screen-based, structured voice-based and free-speech-based cognitive assessment.

Short descriptiontext

Winterlight Labs builds AI-powered speech analysis technology that extracts 550+ acoustic and linguistic features from short speech samples to detect and monitor cognitive impairment in Alzheimer's, FTD, depression, schizophrenia and related conditions, sold primarily to top pharmaceutical and life sciences companies for use as clinical trial endpoints.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
speech-based digital biomarkers, cognitive assessment technology, clinical trial endpoints, voice biomarker analysis, neurological disease detection
Industry2 codes
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAAAI
Speech Recognition, Dictation & Medical Transcription Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Electronic Health Records (EHR/EMR) & Clinical Documentation
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Clinical Trial Digital Biomarkers
Social media profiles2 records
GTM motion5 records

Each record includes

Type, Description, Source

Revenue model4 records
1Clinical research collaborations with life sciences / pharmaceutical companies
TypeProfessional Services
Description

Winterlight supports life science partners throughout clinical trials with site onboarding, data collection, speech analysis and results interpretation. The Winterlight Assessment is deployed in a dozen clinical trials spanning Alzheimer's disease, frontotemporal dementia, depression, bipolar disorder and schizophrenia; described as generating revenue from pharma and life sciences customers (e.g., Genentech, Janssen, Alector, Vivoryon, Cortexyme).

winterlightlabs.com
2Technology licensing (e.g., Pear Therapeutics)
TypeLicensing Royalties
Description

Pear Therapeutics licensed Winterlight's machine learning-based voice digital biomarkers to develop and clinically validate digital biomarkers for Alzheimer's disease, depression, insomnia, schizophrenia, opioid use disorder, and substance use disorder — speech-based biomarkers to titrate dose and modify treatment within prescription digital therapeutics.

winterlightlabs.com
3Speech Analysis API access
TypeSubscription Recurring
Description

Partners access clinically validated speech-based biomarkers via API; can be used to receive analyses for speech data already collected, or to integrate Winterlight Assessment into apps or devices that continuously collect speech. (Public pricing not disclosed; waitlist sign-up required.)

winterlightlabs.com
4Clinical Assessment Quality Assurance (Ratings QA) services
TypeProfessional Services
Description

Automated quality review of 100% of clinical assessments in trials (Audio QA, Content QA, Clinical Scoring) for assessments such as ADAS-Cog, CDR, MMSE, MoCA, PANSS, HAM-D.

winterlightlabs.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Winterlight Labs builds a speech-analysis platform that extracts 550+ acoustic and linguistic features from short (1-5 minute) speech samples to produce digital biomarkers for detecting and monitoring cognitive impairment associated with dementia, Alzheimer's, frontotemporal dementia, Parkinson's, ALS, depression, schizophrenia and other neurological and psychiatric conditions. Its core products are the tablet-based Winterlight Assessment, a Speech Analysis API, and a Clinical Assessment Ratings Quality Assurance service used in CNS clinical trials run by life sciences partners.

Differentiator
Functional benefit
Problem solved
Product and service3 records
1Winterlight Assessment
CategoryClinical Trial Digital Biomarkers
Description

A tablet-based cognitive assessment that analyzes short snippets of natural speech to detect and monitor cognitive impairment associated with dementia, Alzheimer's, aphasia, frontotemporal dementia, depression and other conditions. It extracts over 550 acoustic and linguistic features, supports customizable tasks, and can be administered in clinic or remotely on a patient's own device, with reported accuracy of 82%-100% in peer-reviewed studies. Used by life sciences partners as a clinical trial endpoint and by senior care operators for cognitive screening.

2Winterlight Speech Analysis API
CategoryAPI / Developer Integration
Description

API allowing partners and developers to either submit speech data they have already collected for analysis or embed the Winterlight Assessment within their own application or device that continuously collects speech, returning clinically validated speech-based biomarker outputs in English, French, Spanish, and German.

3Clinical Assessment Ratings Quality Assurance
CategoryClinical Trial Quality Assurance Services
Description

Automated quality review service for clinical assessments administered in clinical trials (including ADAS-Cog, CDR, MMSE, MoCA, PANSS, HAM-D), providing audio QA, content QA and clinical scoring, including rater identification across visits and detection of duplicate participant enrolment.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership18 partners
Strategic tierFlagship — Parent Company And AcquirerTypeStrategic or Co-development PartnerAnnounced on2023-01-11
Description

Cambridge Cognition acquired Winterlight Labs in January 2023 to lead in voice and digital biomarkers for clinical trials. The combined organization offers screen-based, structured voice-based and free-speech based cognitive assessments. Cambridge Cognition stated it would welcome 28 new colleagues from Winterlight, bringing together proprietary free-speech analysis technology with Cambridge Cognition's existing short structured verbal cognitive assessments.

Strategic tierCore / FlagshipTypeStrategic or Co-development PartnerAnnounced on2022-10-04
Description

Multi-year collaboration on Alzheimer's disease speech biomarker research using data from Genentech's Tauriel trial of semorinemab in early-stage AD (NCT03289143). Winterlight's platform processed recordings of conventional Clinical Dementia Rating (CDR) administrations from 101 patients, generating 500+ acoustic and linguistic markers combined into a composite speech score that showed comparable utility to CDR Sum of Boxes and ADAS-Cog. Also presented research at ADPD 2022 (March 2022) linking speech characteristics to cerebral tau accumulation measured by tau PET imaging.

3Alzheimer Center Amsterdam (Amsterdam UMC)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-29
Description

Collaboration (funded by Dutch Ministry of Health via Health~Holland) to decentralize patient assessments in preclinical Alzheimer's research. Alzheimer Center Amsterdam will develop a remote measurement toolbox integrating Winterlight's digital speech assessments to capture subtle changes in cognitive health in the earliest stages of Alzheimer's disease. Jessica Robin (Director, Clinical Research) and Liam Kaufman (CEO) lead the Winterlight side; Sietske Sikkes (Associate Professor) leads at Amsterdam UMC.

winterlightlabs.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-11-04
Description

Collaboration to assess whether vocal biomarkers can help detect individuals with mood disorders and suicide risk, conducted in partnership with Dr. Flavio Kapczinski and team from the Department of Psychiatry & Behavioural Neurosciences. Enhances Winterlight's research program for developing and validating digital speech measures in mood disorders.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-11-04
Description

Winterlight technology used in a study exploring speech as a predictor of psychotic relapse in young adults with Schizophrenia Spectrum Disorders. Participants are followed over a year to characterize speech/language changes relative to fluctuating clinical symptoms.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-11-04
Description

Collaboration to examine how speech is affected in individuals with essential tremor. Dr. Rabin's team uses the Winterlight speech assessment before and after magnetic resonance guided focused ultrasound treatment to discover novel insights into how speech is affected by essential tremor and treatments for the condition.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-11-04
Description

Collaboration to study speech patterns in patients with cirrhosis longitudinally, building on prior work showing slowed speech occurs in hepatic encephalopathy. Dr. Bloom's research group determines whether at-home speech assessments can monitor patient health and predict episodes of overt hepatic encephalopathy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-30
Description

Winterlight Labs participated in DiMe's "Tour of Duty" alongside other leading organizations in life sciences, healthcare, technology and regulatory affairs to develop 100+ new resources for the Digital Clinical Measures Playbook, advancing adoption of digital clinical measures in clinical research and practice.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-03-18
Description

Winterlight Labs' speech assessment is used as an exploratory parameter in Vivoryon Therapeutics' Phase 2b VIVIAD clinical trial of PQ912 in early Alzheimer's disease, alongside EEG and blood-based biomarkers from Nordic Bioscience, to strengthen PQ912's data package with innovative, less invasive diagnostic tools.

10Pear Therapeutics
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-01-07
Description

Pear Therapeutics licensed Winterlight's machine learning-based voice digital biomarkers to develop and clinically validate digital biomarkers for Alzheimer's disease, depression, insomnia, schizophrenia, opioid use disorder and substance use disorder. The biomarkers will be embedded within Pear's prescription digital therapeutics (PDTs) to titrate dose and modify treatment type.

winterlightlabs.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-07-09
Description

Developing vocal biomarkers for monitoring disease progression in frontotemporal dementia (FTD) patients. Deployed Winterlight's speech-based digital biomarker across two projects: an ongoing year-long observational study with caregiver-administered tablet assessments, and development of FTD-specific biomarkers as an exploratory endpoint in Alector's upcoming Phase 2 clinical trial for AL001.

Strategic tierCore / FlagshipTypeStrategic or Co-development PartnerAnnounced on2019-01-07
Description

Collaboration (facilitated by Johnson & Johnson Innovation LLC) to develop a sensitive digital biomarker distinguishing patients with mild cognitive impairment (early stage Alzheimer's) from healthy elderly subjects. Winterlight also participated in a 2017 J&J feasibility study with Janssen R&D to evaluate performance of its algorithms on speech samples collected in Janssen clinical trials in Alzheimer's and neurodegenerative diseases.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-10-25
Description

Cortexyme used Winterlight's cognitive assessment in its Phase 1B clinical trial for Alzheimer's disease (COR388, a bacterial protease inhibitor). Winterlight's assessment detected statistically significant improvements from baseline to endpoint in the treatment group (n=6) where MMSE and CANTAB measures did not, demonstrating the platform's sensitivity in clinical trials.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-01-25
Description

Winterlight joined Revera's Innovators in Aging program to pilot its speech-based cognitive assessment at one of Revera's senior care homes in Toronto with 50 participants over 6 months. Pilot funded via the Ontario Centres of Excellence (OCE) Health Technology Fund (HTF). Each participant received the Winterlight assessment once per month plus gold-standard pen-and-paper assessments at months 1 and 6.

Strategic tierCoreTypeOthersAnnounced on2017-01-01
Description

Winterlight Labs joined JLABS @ Toronto, a 40,000 square-foot life science innovation center run on a "no strings attached" model (J&J Innovation takes no equity stake). JLABS @ Toronto provided flexible lab infrastructure to support Winterlight's development and commercialization.

Strategic tierMinorTypeOthersAnnounced on2016-07-26
Description

Pan-Canadian research network that supported Winterlight Labs from inception and hosted the startup pitch competition Winterlight won in 2016 ("Technology to Support People with Dementia").

Strategic tierMinorTypeOthersAnnounced on2015-01-01
Description

Listed as a supporter / partner organization on Winterlight Labs' homepage. The Ontario Brain Institute has supported Winterlight's development as a Toronto-based neuroscience technology company.

TypeOthersAnnounced on2015-01-01
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Signant Health is a large clinical trial technology provider offering eCOA, rater training, and quality assurance services (including from the MedAvante-ProPhase acquisition) for CNS trials. It competes with Winterlight's Ratings Quality Assurance product and broader CNS trial endpoint portfolio.

TypeDirect peer
Description

Altoida is a digital biomarker company that uses AI-driven cognitive assessments (including AR-based and speech-based tasks) to detect early Alzheimer's and other neurological conditions, targeting pharma clinical trials and clinical use — closely comparable to Winterlight's CNS digital biomarker offering.

TypeBroad incumbent
Description

Verily (an Alphabet company) develops digital biomarkers and clinical research tools across multiple therapeutic areas including neurodegeneration and psychiatry, making it a broad incumbent competitor in pharma-facing digital endpoint technology.

TypeEmerging player
Description

Cumulus Neuroscience provides a remote, multimodal digital biomarker platform (combining speech, cognition, and other assessments) for CNS clinical trials in Alzheimer's, depression, and other indications — closely comparable to Winterlight's decentralized speech assessment capabilities.

TypeEmerging player
Description

Savonix offers a digital neurocognitive assessment platform that uses tablet-based tests to evaluate cognition in clinical and research settings. It is an emerging player with overlapping capabilities in digital cognitive screening and CNS assessment, competing for similar clinical research customers.

TypeDirect peer
Description

Cogstate provides computerized cognitive assessment tools for clinical trials and healthcare, including CANTAB. Like Winterlight, it sells validated digital cognitive endpoints to top-tier pharma and offers both screen-based and remote assessment capabilities, making it a direct competitor for CNS clinical trial endpoint contracts.

TypeDirect peer
Description

BrainCheck provides digital cognitive assessment software using tablet-based tests to detect and monitor cognitive impairment across dementia, concussion, and other indications, with both clinical and clinical research applications — overlapping directly with Winterlight's tablet-based cognitive assessment product.

TypeDirect peer
Description

Linus Health offers AI-powered digital cognitive assessments that combine speech, drawing, and tablet-based tasks to detect early signs of cognitive impairment and dementia. It serves both healthcare providers and clinical research customers in the same CNS digital biomarker category as Winterlight.

9Pear Therapeutics
TypeEmerging player
Description

Pear Therapeutics licensed Winterlight's voice digital biomarkers to embed in prescription digital therapeutics across CNS indications. While a customer rather than a direct competitor, Pear is a comparable emerging digital therapeutics player operating in overlapping CNS indications.

TypeBroad incumbent
Description

Cambridge Cognition acquired Winterlight in January 2023 and is now the parent company. As a broader incumbent, it offers CANTAB-based screen-based and structured voice cognitive assessments to life sciences customers, directly overlapping with Winterlight's clinical research product line.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Winterlight Labs

Clinical Trial Digital Biomarkerswinterlightlabs.com

Winterlight Labs builds AI-powered speech analysis technology that extracts 550+ acoustic and linguistic features from short speech samples to detect and monitor cognitive impairment in Alzheimer's, FTD, depression, schizophrenia and related conditions, sold primarily to top pharmaceutical and life sciences companies for use as clinical trial endpoints.

What Winterlight Labs does

Winterlight Labs is a Toronto-based digital health company, founded in 2015 and spun out of the University of Toronto, that builds proprietary speech-analysis technology to detect and monitor cognitive impairment from short (1-5 minute) recorded speech samples. The platform combines natural language processing, computational linguistics, cognitive neuroscience and machine learning to extract 550+ acoustic and linguistic features (e.g., informativeness, coherence, repetition, preposition/pronoun use, speaking rate, pauses, filled pauses, spectral composition) and produce speech-based digital biomarkers for conditions including Alzheimer's disease, frontotemporal dementia, mild cognitive impairment, Parkinson's, ALS, depression, schizophrenia and hepatic encephalopathy. Multi-language linguistic analysis is supported across English, French, Spanish and German via the Universal Dependencies framework. The product surface comprises the Winterlight Assessment (a tablet- or device-based cognitive assessment for in-clinic or remote use), a Speech Analysis API (waitlist-based) for partners with existing speech data, and a Clinical Assessment Ratings Quality Assurance service that automates 100% review of clinical assessment administration and scoring (ADAS-Cog, CDR, MMSE, MoCA, PANSS, HAM-D).

Winterlight's go-to-market is predominantly enterprise sales to pharmaceutical and life sciences customers (the company states it is "trusted by five of the top ten Life Sciences companies"), with named deployments across a dozen clinical trials at Genentech, Janssen Pharmaceuticals, Alector, Vivoryon Therapeutics, Cortexyme and Pear Therapeutics. Revenue is generated through clinical research collaborations (professional services for site onboarding, data collection, analysis and interpretation), technology licensing (e.g., Pear Therapeutics for prescription digital therapeutics), and prospective API subscriptions. Senior care pilots (e.g., Revera) and academic collaborations (University of Toronto, Amsterdam UMC, McMaster, CAMH, Sunnybrook, University of Michigan) serve as validation and data-collection channels rather than primary monetization. In November 2019 the company closed a CAD 5.6M oversubscribed Series A led by Hikma Ventures; in January 2023 Cambridge Cognition Holdings Plc acquired Winterlight for approximately $8.6M, integrating it as a wholly owned subsidiary with combined capabilities in screen-based, structured voice-based and free-speech-based cognitive assessment.

Winterlight Labs firmographics

Firmographics
Name
Winterlight Labs
Legal name
Winterlight Labs, Inc.
Website
https://winterlightlabs.com
Company type
Private
Founded year
2015
Operating status
Acquired
Headcount range
11–50 employees
Short description
Winterlight Labs builds AI-powered speech analysis technology that extracts 550+ acoustic and linguistic features from short speech samples to detect and monitor cognitive impairment in Alzheimer's, FTD, depression, schizophrenia and related conditions, sold primarily to top pharmaceutical and life sciences companies for use as clinical trial endpoints.
Ownership category
akta.pro rank

Winterlight Labs industry classification

Industry
Product category
Clinical Trial Digital Biomarkers
NAICS
Medical Laboratories (621511)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAAAI
Speech Recognition, Dictation & Medical Transcription Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Electronic Health Records (EHR/EMR) & Clinical Documentation

Keywords

  • Speech-based digital biomarkers
  • Cognitive assessment technology
  • Clinical trial endpoints
  • Voice biomarker analysis
  • Neurological disease detection

Where Winterlight Labs is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Winterlight Labs business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical research collaborations with life sciences / pharmaceutical companies: Winterlight supports life science partners throughout clinical trials with site onboarding, data collection, speech analysis and results interpretation. The Winterlight Assessment is deployed in a dozen clinical trials spanning Alzheimer's disease, frontotemporal dementia, depression, bipolar disorder and schizophrenia; described as generating revenue from pharma and life sciences customers (e.g., Genentech, Janssen, Alector, Vivoryon, Cortexyme).
  2. Technology licensing (e.g., Pear Therapeutics): Pear Therapeutics licensed Winterlight's machine learning-based voice digital biomarkers to develop and clinically validate digital biomarkers for Alzheimer's disease, depression, insomnia, schizophrenia, opioid use disorder, and substance use disorder — speech-based biomarkers to titrate dose and modify treatment within prescription digital therapeutics.
  3. Speech Analysis API access: Partners access clinically validated speech-based biomarkers via API; can be used to receive analyses for speech data already collected, or to integrate Winterlight Assessment into apps or devices that continuously collect speech. (Public pricing not disclosed; waitlist sign-up required.)
  4. Clinical Assessment Quality Assurance (Ratings QA) services: Automated quality review of 100% of clinical assessments in trials (Audio QA, Content QA, Clinical Scoring) for assessments such as ADAS-Cog, CDR, MMSE, MoCA, PANSS, HAM-D.

Go-to-market motion5 records

Distribution channels4 records

Marketing channels6 records

Winterlight Labs product offering

Product offering

Core offering

Winterlight Labs builds a speech-analysis platform that extracts 550+ acoustic and linguistic features from short (1-5 minute) speech samples to produce digital biomarkers for detecting and monitoring cognitive impairment associated with dementia, Alzheimer's, frontotemporal dementia, Parkinson's, ALS, depression, schizophrenia and other neurological and psychiatric conditions. Its core products are the tablet-based Winterlight Assessment, a Speech Analysis API, and a Clinical Assessment Ratings Quality Assurance service used in CNS clinical trials run by life sciences partners.

Differentiator

Problem solved

Functional benefit

Products and services

  • Winterlight Assessment A tablet-based cognitive assessment that analyzes short snippets of natural speech to detect and monitor cognitive impairment associated with dementia, Alzheimer's, aphasia, frontotemporal dementia, depression and other conditions. It extracts over 550 acoustic and linguistic features, supports customizable tasks, and can be administered in clinic or remotely on a patient's own device, with reported accuracy of 82%-100% in peer-reviewed studies. Used by life sciences partners as a clinical trial endpoint and by senior care operators for cognitive screening.
  • Winterlight Speech Analysis API API allowing partners and developers to either submit speech data they have already collected for analysis or embed the Winterlight Assessment within their own application or device that continuously collects speech, returning clinically validated speech-based biomarker outputs in English, French, Spanish, and German.
  • Clinical Assessment Ratings Quality Assurance Automated quality review service for clinical assessments administered in clinical trials (including ADAS-Cog, CDR, MMSE, MoCA, PANSS, HAM-D), providing audio QA, content QA and clinical scoring, including rater identification across visits and detection of duplicate participant enrolment.

Companies that use Winterlight Labs

Customer profile

Named customers8 records

Segments5 records

Ideal customer profiles4 records

Winterlight Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature9 records

Winterlight Labs partnerships and signals

Strategic signal

Partnerships

18 partnerships are on record, tiered flagship — parent company and acquirer, core / flagship, core, minor and major.

  • Cambridge Cognitionflagship — parent company and acquirerStrategic or Co-development Partner · 11 January 2023Cambridge Cognition acquired Winterlight Labs in January 2023 to lead in voice and digital biomarkers for clinical trials. The combined organization offers screen-based, structured voice-based and free-speech based cognitive assessments. Cambridge Cognition stated it would welcome 28 new colleagues from Winterlight, bringing together proprietary free-speech analysis technology with Cambridge Cognition's existing short structured verbal cognitive assessments.
  • Genentech (Roche Group)core / flagshipStrategic or Co-development Partner · 4 October 2022Multi-year collaboration on Alzheimer's disease speech biomarker research using data from Genentech's Tauriel trial of semorinemab in early-stage AD (NCT03289143). Winterlight's platform processed recordings of conventional Clinical Dementia Rating (CDR) administrations from 101 patients, generating 500+ acoustic and linguistic markers combined into a composite speech score that showed comparable utility to CDR Sum of Boxes and ADAS-Cog. Also presented research at ADPD 2022 (March 2022) linking speech characteristics to cerebral tau accumulation measured by tau PET imaging.
  • Alzheimer Center Amsterdam (Amsterdam UMC)coreStrategic or Co-development Partner · 29 March 2022Collaboration (funded by Dutch Ministry of Health via Health~Holland) to decentralize patient assessments in preclinical Alzheimer's research. Alzheimer Center Amsterdam will develop a remote measurement toolbox integrating Winterlight's digital speech assessments to capture subtle changes in cognitive health in the earliest stages of Alzheimer's disease. Jessica Robin (Director, Clinical Research) and Liam Kaufman (CEO) lead the Winterlight side; Sietske Sikkes (Associate Professor) leads at Amsterdam UMC.
  • McMaster University (Dr. Flavio Kapczinski)minorStrategic or Co-development Partner · 4 November 2021Collaboration to assess whether vocal biomarkers can help detect individuals with mood disorders and suicide risk, conducted in partnership with Dr. Flavio Kapczinski and team from the Department of Psychiatry & Behavioural Neurosciences. Enhances Winterlight's research program for developing and validating digital speech measures in mood disorders.
  • Centre for Addiction and Mental Health (CAMH) — Dr. Farooq Naeem & Dr. Anthony YeungminorStrategic or Co-development Partner · 4 November 2021Winterlight technology used in a study exploring speech as a predictor of psychotic relapse in young adults with Schizophrenia Spectrum Disorders. Participants are followed over a year to characterize speech/language changes relative to fluctuating clinical symptoms.
  • Sunnybrook Research Institute (Harquail Centre for Neuromodulation) — Dr. Jenny RabinminorStrategic or Co-development Partner · 4 November 2021Collaboration to examine how speech is affected in individuals with essential tremor. Dr. Rabin's team uses the Winterlight speech assessment before and after magnetic resonance guided focused ultrasound treatment to discover novel insights into how speech is affected by essential tremor and treatments for the condition.
  • University of Michigan — Dr. Patricia BloomminorStrategic or Co-development Partner · 4 November 2021Collaboration to study speech patterns in patients with cirrhosis longitudinally, building on prior work showing slowed speech occurs in hepatic encephalopathy. Dr. Bloom's research group determines whether at-home speech assessments can monitor patient health and predict episodes of overt hepatic encephalopathy.
  • Digital Medicine Society (DiMe)coreStrategic or Co-development Partner · 30 April 2021Winterlight Labs participated in DiMe's "Tour of Duty" alongside other leading organizations in life sciences, healthcare, technology and regulatory affairs to develop 100+ new resources for the Digital Clinical Measures Playbook, advancing adoption of digital clinical measures in clinical research and practice.
  • Vivoryon TherapeuticscoreStrategic or Co-development Partner · 18 March 2020Winterlight Labs' speech assessment is used as an exploratory parameter in Vivoryon Therapeutics' Phase 2b VIVIAD clinical trial of PQ912 in early Alzheimer's disease, alongside EEG and blood-based biomarkers from Nordic Bioscience, to strengthen PQ912's data package with innovative, less invasive diagnostic tools.
  • Pear TherapeuticsmajorOEM/ Whitelabel/ Licensing Partner · 7 January 2020Pear Therapeutics licensed Winterlight's machine learning-based voice digital biomarkers to develop and clinically validate digital biomarkers for Alzheimer's disease, depression, insomnia, schizophrenia, opioid use disorder and substance use disorder. The biomarkers will be embedded within Pear's prescription digital therapeutics (PDTs) to titrate dose and modify treatment type.
  • AlectorcoreStrategic or Co-development Partner · 9 July 2019Developing vocal biomarkers for monitoring disease progression in frontotemporal dementia (FTD) patients. Deployed Winterlight's speech-based digital biomarker across two projects: an ongoing year-long observational study with caregiver-administered tablet assessments, and development of FTD-specific biomarkers as an exploratory endpoint in Alector's upcoming Phase 2 clinical trial for AL001.
  • Janssen Pharmaceuticals (Johnson & Johnson)core / flagshipStrategic or Co-development Partner · 7 January 2019Collaboration (facilitated by Johnson & Johnson Innovation LLC) to develop a sensitive digital biomarker distinguishing patients with mild cognitive impairment (early stage Alzheimer's) from healthy elderly subjects. Winterlight also participated in a 2017 J&J feasibility study with Janssen R&D to evaluate performance of its algorithms on speech samples collected in Janssen clinical trials in Alzheimer's and neurodegenerative diseases.
  • CortexymeminorStrategic or Co-development Partner · 25 October 2018Cortexyme used Winterlight's cognitive assessment in its Phase 1B clinical trial for Alzheimer's disease (COR388, a bacterial protease inhibitor). Winterlight's assessment detected statistically significant improvements from baseline to endpoint in the treatment group (n=6) where MMSE and CANTAB measures did not, demonstrating the platform's sensitivity in clinical trials.
  • ReveraminorStrategic or Co-development Partner · 25 January 2018Winterlight joined Revera's Innovators in Aging program to pilot its speech-based cognitive assessment at one of Revera's senior care homes in Toronto with 50 participants over 6 months. Pilot funded via the Ontario Centres of Excellence (OCE) Health Technology Fund (HTF). Each participant received the Winterlight assessment once per month plus gold-standard pen-and-paper assessments at months 1 and 6.
  • Johnson & Johnson JLABS @ TorontocoreOthers · 1 January 2017Winterlight Labs joined JLABS @ Toronto, a 40,000 square-foot life science innovation center run on a "no strings attached" model (J&J Innovation takes no equity stake). JLABS @ Toronto provided flexible lab infrastructure to support Winterlight's development and commercialization.
  • AGE-WELL Network of Centres of Excellence (NCE)minorOthers · 26 July 2016Pan-Canadian research network that supported Winterlight Labs from inception and hosted the startup pitch competition Winterlight won in 2016 ("Technology to Support People with Dementia").
  • Ontario Brain InstituteminorOthers · 1 January 2015Listed as a supporter / partner organization on Winterlight Labs' homepage. The Ontario Brain Institute has supported Winterlight's development as a Toronto-based neuroscience technology company.
  • MaRS Discovery DistrictOthers · 1 January 2015

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Winterlight Labs competitors and assessment

Company assessment

Broad incumbents

  • Signant Health: Signant Health is a large clinical trial technology provider offering eCOA, rater training, and quality assurance services (including from the MedAvante-ProPhase acquisition) for CNS trials. It competes with Winterlight's Ratings Quality Assurance product and broader CNS trial endpoint portfolio.
  • Verily Life Sciences: Verily (an Alphabet company) develops digital biomarkers and clinical research tools across multiple therapeutic areas including neurodegeneration and psychiatry, making it a broad incumbent competitor in pharma-facing digital endpoint technology.
  • Cambridge Cognition: Cambridge Cognition acquired Winterlight in January 2023 and is now the parent company. As a broader incumbent, it offers CANTAB-based screen-based and structured voice cognitive assessments to life sciences customers, directly overlapping with Winterlight's clinical research product line.

Direct peers

  • Altoida: Altoida is a digital biomarker company that uses AI-driven cognitive assessments (including AR-based and speech-based tasks) to detect early Alzheimer's and other neurological conditions, targeting pharma clinical trials and clinical use — closely comparable to Winterlight's CNS digital biomarker offering.
  • Cogstate: Cogstate provides computerized cognitive assessment tools for clinical trials and healthcare, including CANTAB. Like Winterlight, it sells validated digital cognitive endpoints to top-tier pharma and offers both screen-based and remote assessment capabilities, making it a direct competitor for CNS clinical trial endpoint contracts.
  • BrainCheck: BrainCheck provides digital cognitive assessment software using tablet-based tests to detect and monitor cognitive impairment across dementia, concussion, and other indications, with both clinical and clinical research applications — overlapping directly with Winterlight's tablet-based cognitive assessment product.
  • Linus Health: Linus Health offers AI-powered digital cognitive assessments that combine speech, drawing, and tablet-based tasks to detect early signs of cognitive impairment and dementia. It serves both healthcare providers and clinical research customers in the same CNS digital biomarker category as Winterlight.

Emerging players

  • Cumulus Neuroscience: Cumulus Neuroscience provides a remote, multimodal digital biomarker platform (combining speech, cognition, and other assessments) for CNS clinical trials in Alzheimer's, depression, and other indications — closely comparable to Winterlight's decentralized speech assessment capabilities.
  • Savonix: Savonix offers a digital neurocognitive assessment platform that uses tablet-based tests to evaluate cognition in clinical and research settings. It is an emerging player with overlapping capabilities in digital cognitive screening and CNS assessment, competing for similar clinical research customers.
  • Pear Therapeutics: Pear Therapeutics licensed Winterlight's voice digital biomarkers to embed in prescription digital therapeutics across CNS indications. While a customer rather than a direct competitor, Pear is a comparable emerging digital therapeutics player operating in overlapping CNS indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Winterlight Labs social profiles

Digital presence

Winterlight Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Winterlight Labs leadership team

Management profile

Number of profiles

Profiles7 records

Winterlight Labs funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Winterlight Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Winterlight Labs

What does Winterlight Labs do?

Winterlight Labs builds a speech-analysis platform that extracts 550+ acoustic and linguistic features from short (1-5 minute) speech samples to produce digital biomarkers for detecting and monitoring cognitive impairment associated with dementia, Alzheimer's, frontotemporal dementia, Parkinson's, ALS, depression, schizophrenia and other neurological and psychiatric conditions. Its core products are the tablet-based Winterlight Assessment, a Speech Analysis API, and a Clinical Assessment Ratings Quality Assurance service used in CNS clinical trials run by life sciences partners.

Is Winterlight Labs a public or private company?

Winterlight Labs is a private company. It is classified as corporate owned and is currently acquired.

When was Winterlight Labs founded?

Winterlight Labs was founded in 2015. It employs 11 to 50 people.

Where is Winterlight Labs based?

Winterlight Labs is headquartered in Toronto, Canada, in the North America region.

How does Winterlight Labs make money?

Four revenue lines are on record. Clinical research collaborations with life sciences / pharmaceutical companies are the primary driver. The others are technology licensing (e.g., Pear Therapeutics), speech Analysis API access and clinical Assessment Quality Assurance (Ratings QA) services.

Who are Winterlight Labs's main competitors?

Broad incumbents on record are Signant Health, Verily Life Sciences and Cambridge Cognition. Direct peers are Altoida, Cogstate, BrainCheck and Linus Health. Emerging players are Cumulus Neuroscience, Savonix and Pear Therapeutics.

Does Winterlight Labs have an API?

Yes. Winterlight Labs offers a Speech Analysis API that allows developers and partners to receive speech-based biomarker analyses. Use cases include: (1) submitting speech data that has already been collected to receive analysis results, and (2) integrating the Winterlight Assessment into a customer application or device that continuously collects speech to receive fast, ongoing biomarker results. The API supports English, with French, Spanish, and German linguistic analysis available. Access requires signing up for a waitlist; no public documentation URL, SDK, authentication method, rate limit, or versioning details are provided in the source material.

What industry is Winterlight Labs in?

Winterlight Labs's product category is Clinical Trial Digital Biomarkers. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLACAAAI, Speech Recognition, Dictation & Medical Transcription Platforms. Its NAICS code is 621511 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comVocal Biomarkers Market Outlook Signals Expansion To $7.4 Billion Through 2030The vocal biomarkers market is projected to reach $7.41 billion by 2030, growing at a 16.8% CAGR. It is expected to expand from $3.35 billion in 2025 to $3.98 billion in 2026. Cambridge Cognition acquired Winterlight Labs for $8.6 million in January 2023.Market Research BlogVoice Biomarkers Market to Hit $5.4 Billion by 2035 – Here’s What’s Driving ItThe global voice biomarker market is projected to grow from $1,081.3 million in 2024 to approximately $5.4 billion by 2035, driven by advancements in AI and the rise of telemedicine. Key industry players such as Sonde Health, Winterlight Labs, and Qualcomm are actively partnering or consolidating to integrate these non-invasive diagnostic tools into healthcare platforms.WinterlightlabsCambridge Cognition and Winterlight Labs join forces to lead in voice and digital biomarkers for clinical trialsCambridge Cognition has acquired Winterlight Labs to combine their respective technologies in voice and digital biomarkers for clinical trials. This strategic move aims to create a market-leading position by integrating Cambridge Cognition's structured assessments with Winterlight's free-speech analysis capabilities. The combined entity intends to leverage this expanded expertise to drive innovation in drug development and improve outcomes for CNS disorders.AI Business InformsNew Trend in Medical AI: Diagnosing Diseases From SpeechThe FDA's AI/ML-enabled medical device approvals rose 52% to 521, with most in radiology. A new trend uses speech-based vocal biomarkers for diagnosis, with Aural Analytics registered a device and Winterlight Labs running trials. Challenges include unclear FDA pathways, false positives, and data privacy concerns.Wamda.comHikma Ventures invests in Winterlight LabsHikma Ventures led a C$5.6 million oversubscribed financing round for Winterlight Labs, with participation from First Star Ventures, Pacific Health Ventures, and others. Winterlight Labs is developing AI technology that analyzes one-minute speech samples to detect cognitive disorders like dementia and aphasia. The company plans to expand its disease areas and geographies, especially in the Middle East and North Africa.MobiHealthNewsSpeech AI-enabled cognitive health company Winterlight Labs scores $4.23MWinterlight Labs, a Toronto-based speech AI company for cognitive health, raised $4.23 million in funding led by Hikma Ventures. The company plans to use the funds to expand its product to detect conditions like schizophrenia and multiple sclerosis, and add new languages.PR NewswireWinterlight Labs, Inc. Enters Collaboration with Johnson & Johnson Innovation to Develop a Digital Biomarker for Diagnosis of Early Stage Alzheimer's DiseaseWinterlight Labs, a Toronto-based company specializing in AI-powered speech analysis for neurological assessment, has entered a collaboration with Janssen Pharmaceuticals (part of Johnson & Johnson) to develop a digital biomarker capable of detecting mild cognitive impairment, an early stage of Alzheimer's Disease. The collaboration aims to leverage Winterlight's existing technology, which extracts 500 features from speech and currently achieves 91% accuracy in distinguishing Alzheimer's from healthy aging using just two minutes of speech. The partnership seeks to enable therapeutic intervention during the pre-symptomatic period of Alzheimer's, when treatment has the greatest chance of providing meaningful benefit to patients.IEEE SpectrumTech Watches You for Digital Symptoms of Brain DisordersThree startups—Mindstrong Health, NeuraMetrix, and WinterLight Labs—use digital data from typing, speech, and smartphone use to detect brain disorders. Mindstrong's app is used in trials for schizophrenia and depression, while NeuraMetrix claims 99.9% accuracy for Parkinson's, and WinterLight targets Alzheimer's monitoring.The TelegraphInside the AI healthcare revolution: meeting the robots that can detect Alzheimer's and depressionWinterLight Labs' AI system can detect Alzheimer's in 45 seconds by analyzing speech patterns, achieving about 82% accuracy. The company also developed a robot named Ludwig that assesses speech and predicts depression risk. The technology is currently piloted in retirement homes and hospitals, not yet for diagnosis.